$NMTC

Christianson Mark sold $32K of NMTC

Christianson Mark (Market Development Director) sold 10,000 shares of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) at $3.18 on 2026-06-30.

Original reporting
SEC EDGAR · Christianson Mark
Published Jul 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NMTC
Neutral
medium confidence
Mentioned
$NMTC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NMTCNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by Mark Christianson (Market Development Director) of 10,000 shares at $3.1773, totaling $31,773, with holdings after the trade of 20,692 shares.

02

Market read

Traders may monitor for continued insider selling, but the filing alone does not provide a fundamental catalyst.

03

What to watch

The article does not state total position size change beyond the post-transaction holdings, nor does it provide context such as prior sales cadence or tax-related selling.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-02, sale dated 2026-06-30

Background

This is an SEC Form 4 insider transaction disclosure for NEUROONE MEDICAL TECHNOLOGIES (NMTC).

Company-level read

Ticker impact

$NMTCNeutralMedium confidence
Context

NEUROONE MEDICAL TECHNOLOGIES Form 4 shows insider Mark Christianson sold 10,000 shares at $3.1773 on 2026-06-30.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless follow-on selling appears.

Evidence & confidence

The filing is a primary-source Form 4, but it is not tied to earnings, guidance, contracts, or regulatory actions. The disclosed size is moderate and the article provides no additional context on company performance or future plans.

Market effects

No sector-level implications; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • NEUROONE MEDICAL TECHNOLOGIES Corp

    Subject of the Form 4 insider sale disclosure.

  • Christianson Mark

    Market Development Director who sold shares.

Related articles